BMH BRÄUTIGAM ADVISES ORKILA CAPITAL ON INVESTMENT IN CANNAMEDICAL PHARMA GMBH
BMH BRÄUTIGAM advised the US venture capital fund Orkila Capital on the EUR 15 Million investment in Cannamedical Pharma GmbH.
Cannamedical Pharma GmbH is active in the highly dynamic distribution market of medical cannabis. In 2017, the use of cannabis for medical reasons was legalized in Germany. Since then, cannabis may be prescribed by doctors for treatment of more than 80 diseases and may be sold by pharmacies. Cannamedical Pharma GmbH is one of the distribution pioneers in this market and has a worldwide network of suppliers. In the course of this transaction, Orkila Capital obtains a significant minority shareholding in Cannamedical Pharma GmbH.
Orkila Capital is an established US venture capital fund with focus on the technology, entertainment and consumer market industries. Orkila Capital’s portfolio includes the Danish microbrewery company Mikkeller and the footwear and accessories company FEIT. BMH BRÄUTIGAM has advised Orkila Capital for the first time in this deal. Over the last years, BMH BRÄUTIGAM has continually expanded its venture capital practice which advises both reputable founders and German and international investors. Currently, BMH BRÄUTIGAM’s venture capital team consists of seven lawyers.
Team BMH BRÄUTIGAM:
Dr. Patrick Auerbach-Hohl, Dr. Matthias Rüping, Dr. Julian Schroeder, Dr. Annette Schwab, Dr. Alexander Wulff (all Venture Capital)